BIOMAT Database Logo BIOMAT Database Logo

Long-acting beta agonists in asthma therapy. 2004

Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Wake Forest University School of Medicine, Center for Human Genomics, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

UI MeSH Term Description Entries
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068299 Salmeterol Xinafoate A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Salmeterol,Serevent,Xinafoate, Salmeterol
D000068759 Formoterol Fumarate An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate,Arformoterol,BD 40A,Eformoterol,Foradil,Formoterol,Formoterol Fumarate, ((R*,R*)-(+-))-isomer,Formoterol, ((R*,R*)-(+-))-isomer,Oxis
D000305 Adrenal Cortex Hormones HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE. Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000420 Albuterol A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. Salbutamol,2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol,Albuterol Sulfate,Proventil,Sultanol,Ventolin
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
[Update in asthma therapy. Long-acting beta-2 agonists].
August 2006, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Long-acting beta-agonists in asthma.
July 2009, The New England journal of medicine,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Long-acting beta-agonists in asthma.
July 2009, The New England journal of medicine,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Long-acting beta-2 agonists in asthma.
January 2009, The Medical letter on drugs and therapeutics,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Long-acting beta-agonists role in asthma management.
April 2006, The Journal of family practice,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Asthma exacerbations during first therapy with long acting beta 2-agonists.
June 1999, Pharmacy world & science : PWS,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
[Long-acting beta-2 agonists in pediatric asthma therapy--friend or foe].
June 2006, Wiener klinische Wochenschrift,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
[Risk of long-acting beta-2 agonists in asthma].
March 2007, Medicina clinica,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Role of long-acting beta 2 agonists in asthma.
November 1992, Annals of allergy,
Richard W Rissmiller, and Michael J Larj, and Stephen P Peters
Long-acting inhaled beta2-agonists in asthma therapy.
April 1998, Chest,
Copied contents to your clipboard!